publication date: Dec. 7, 2018
Issue 45 - Dec. 7, 2018
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • NCI cuts programs by 5% and non-competing renewals by 3% to maintain paylines in fiscal 2019

    NCI is cutting the budgets of divisions, offices, and centers within the institute by 5 percent to maintain funding for its Research Project Grant pool, which funds a broad range of basic research, as well as clinical trials and health services research.

  • Conversation with The Cancer Letter

    UAB Cancer Center receives $30 million naming gift from O’Neal Industries

    The University of Alabama at Birmingham Comprehensive Cancer Center has received a $30 million gift from O’Neal Industries Inc., a family-owned global business based in Birmingham.

  • In Appreciation

    Lisa Schwartz, expert in overtreatment and pathbreaking educator, dies at 55

    Lisa Schwartz, professor of Medicine and of Community and Family Medicine at Dartmouth Medical School died on November 29 after a seven-year struggle with cancer—a terrible loss to all who knew her.

  • Obituary

    Charles A. Coltman Jr., long-time SWOG chair and co-founder of the San Antonio Breast Cancer Symposium, dies at 88

    Charles A. Coltman Jr., a pioneer of treatment of leukemia and lymphoma, a long-time chair of SWOG, and a co-founder of the San Antonio Breast Cancer Symposium, died after a long illness on Nov. 28. He was 88.

  • In Brief

    • Wafik El-Deiry to lead cancer biology program at Brown 
    • Emory Proton Therapy Center opens
  • TCCL Logo

  • Clinical Roundup

    • Kite announces two-year data for Yescarta in patients with refractory large B-cell lymphoma
    • Kite announces updated data from ZUMA-3 study of KTE-X19 in adult patients with relapsed or refractory ALL 
    • Ibrutinib + rituximab superior to standard treatment for some patients with CLL
    • Data from phase I/II open-label study of BCMA-directed CAR-T cell therapy lcar-b38m show tolerable safety profile, high response and MRD-negative rate in advanced r/r multiple myeloma
    • New long-term data on acalabrutinib in mantle cell lymphoma and CLL
    • Geron announces OS data from IMbark in Imetelstat-treated patients with intermediate or high-risk myelofibrosis and r/r to JAK inhibitor
    • New long-term data on Calquence presented
    • Combination immunotherapy shows high activity against recurrent Hodgkin lymphoma
    • Karyopharm reports positive top-line phase IIb SADAL data for Selinexor in diffuse large B-cell lymphoma
    • Celgene announces initial phase I/II liso-cel data in patients with r/r CLL
  • Drugs & Targets

    • FDA approves Tecentriq + Avastin and carboplatin for initial treatment of specific type of metastatic lung cancer
    • FDA publishes draft guidance on class labeling of in vitro companion diagnostics for classes of drugs in oncology
    • FDA publishes framework document on real-world evidence
  • NCI Trials

    NCI Trials for December

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Copyright (c) 2018 The Cancer Letter Inc.